Ordering Recommendation

May be useful for evaluation of patients with characteristic cutaneous manifestations of dermatomyositis with or without muscle weakness.

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation
Collect

Serum Separator Tube (SST).

Specimen Preparation

Separate from cells ASAP or within 2 hours of collection. Transfer one 1 mL serum aliquots to ARUP Standard Transport Tubes. (Min: 0.5 mL/aliquot)

Storage/Transport Temperature

Refrigerated

Unacceptable Conditions

Hemolyzed, hyperlipemic, icteric, heat-treated or contaminated specimens.

Remarks
Stability

Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year

Methodology

Qualitative Immunoprecipitation/Qualitative Immunoblot

Performed

Sun-Sat

Reported

7-18 days

Reference Interval

Test Number
Components
Reference Interval
  Mi-2 (nuclear helicase protein) Antibody Negative
  P155/140 Antibody Negative
  SAE1 (SUMO activating enzyme) Ab Negative
  MDA5 (CADM-140) Ab Negative
  NXP2 (Nuclear matrix protein-2) Ab Negative
  TIF-1 gamma (155 kDa) Ab Negative

Interpretive Data

Refer to report.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Compliance Category

Laboratory Developed Test (LDT)

Note

Antibodies: Mi-2, P155/140, SAE1, MDA5, NXP2, TIF1-gamma

Hotline History

N/A

CPT Codes

83516 x2; 84182 x4

Components

Component Test Code* Component Chart Name LOINC
2010852 Mi-2 (nuclear helicase protein) Antibody 18485-3
2010855 P155/140 Antibody 8061-4
2013996 Dermatomyositis Interpretive Information 48767-8
3001786 SAE1 (SUMO activating enzyme) Ab 82440-9
3001787 MDA5 (CADM-140) Ab 82424-3
3001788 NXP2 (Nuclear matrix protein-2) Ab 82426-8
3001789 TIF-1 gamma (155 kDa) Ab 82448-2
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

Dermatomyositis Autoantibody Panel